A new review and data synthesis examined the biological reach of targeted protein degradation (TPD) technologies, highlighting therapeutic promise and potential off‑target impacts across organs and species. Authors cataloged outcomes from PROTACs and related modalities, calling attention to systemic effects and species‑specific responses in preclinical models. The analysis provides developers with a reference for toxicity profiling and suggests additional assays to detect ecological or cross‑species hazards as TPD moves from tool compounds toward clinical therapeutics.